Navigation Links
Centra B+ (with cell washing rotor)120 V, 60 Hz

ProductsCentra B+ (with cell washing rotor)120 V, 60 Hz
Company ThermoFisher Scientific
Item Centra B+ (with cell washing rotor)120 V, 60 Hz
Features 
Description The Centra B+ can be used as a manual cell washer, as a companion unit to the Centra W for AHG spins, or as a vacutainer style blood tube centrifuge. Choice of 2 rotors, transparent cell washing rotor: easy to see pellets, securely holds tubes for decant, 2 braking options, aerosol containment for vacutainers, glove friendly membrane panels, cover interlock safety lids, brush less motors.
Info ThermoFisher Scientific
Web site: http://www.thermo.com
Web site: http://www.thermofisher.com/global/en/home.asp

Related medicine products :

1. Centra-GP8
2. Centra CL3R
3. Centra-GP8R
4. Centra-GP8RF
5. Centra-W
6. Centra B+ (with cell washing rotor)120 V, 50 Hz
7. Innotrac Aio! Central
8. Endoalpha Centralized O.R. Control System
9. Centralized Holter Analysis
10. Centra-GP8F
11. Centra-CL5R
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products:
(Date:5/16/2008)... ROCHESTER, Minn., May 16 /PRNewswire-USNewswire...format, by Mayo Clinic in conjunction with the,Nat... * A new study being presented at the American Soc...ract #4020), may change treatment practice,in abou...the basis for,proposed changes to the way colorect...
(Date:5/16/2008)... New data from an international, multicenter Phase...l targeted therapy everolimus (RAD001) significant...static kidney cancer whose disease had worsened on...tzer, MD, an attending physician at Memorial Sloan... the findings on May 31 at the annual meeting of t...
(Date:5/16/2008)... PALM BEACH, Fla., May 16 /PRNewswire-USNewswire... more often by Americans, particularly our,childre...individuals, have,significant hearing loss and the...out of every 100 school age children have some for...on to this social and economic problem,is what led...
(Date:5/16/2008)...J Kwon Presents Urban Health Institute with 10,000... of ASFX.org at Playboy Mansion Fundraiser, LOS A...th 2008, hip-hop,and R & B artist J Kwon known bes...Tipsy," will be presenting the Urban Health Instit...acks worth over $50,000. The donation is,being mad...
Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Drug fends off kidney cancer progression 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:Everybody in the Club Scream O! 2
...ly breast cancer who have been receiving the 30-ye...e modern therapy with the drug//, Arimidex under a...neca. The company AstraZeneca has stated that Ari...ade available to women who have already received a...
...that some homeopathic clinics advice people on not...sk parts of the world.// People planning on takin...d to avoid homeopathic remedies that are claiming ...everal travellers contracted the potentially fatal...
... have performed the first incompatible blood group...Melbourne hospital have performed a kidney transpl...tible blood groups. It was explained that Davorin ...ype O, is now carrying a kidney from his father, w...
...ment claims to have reached, and exceeded, its med...health officials have stated the need// for an add...st year Queensland Health had planned to employ400...ls, 500 more nurses and 300 more doctors, by Decem...
Other Medicine News:Health News:Travellers Cautioned Over The Alternate Remedies For Malaria 2Health News:Queensland Government to Meet its Medical Targets 2
(Date:5/16/2008)...RNewswire-FirstCall/ -- Memory Pharmaceuticals,Cor...several key development,programs at its R&D Day me...eported new clinical data for MEM 1414, its lead P...tivity in humans. In addition, the,Company has nom... from its,5-HT6 antagonist program, and separately...
(Date:5/16/2008)... /- Data from three studies,evaluatin...bin (Hb) levels,and the rate of blood transfusions...n reimbursement for erythropoiesis-stimulating age...ood supply, will be presented at the,American Soci...er this,month. The meeting will take place in Chic...
(Date:5/16/2008)...Results demonstrating that TYKERB and trastuzumab ...sion of progression-free survival (PFS), -- Combi...ide and,outside of the HER2 receptor may create a ...g activity of TYKERB alone despite patients,previ...nd chemotherapy, LONDON and PHILADELPHIA, May 16 ...
(Date:5/16/2008)...iomarkers -- for Lung Cancer Diagnosis and, Identi...f Unknown Primary ...es With High Sensitivity and, Specificity and Co...r Results of microRNA Signature to Identify Tissu...g 90% and Specificity of 99%, REHOVOT, Israel and...
Breaking Medicine Technology:Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 2Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 3Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Tulane University to receive 2414M for international HIV AIDS program 780 1Tulane University to receive 2414M for international HIV AIDS program 780 2Multi Year Compendium of Pharmaceutical Case Studies Available from Best Practices LLC 776 1Multi Year Compendium of Pharmaceutical Case Studies Available from Best Practices LLC 776 2Pharmaceutical Manufacturing Quality 3A Optimizing Your Internal Process for FDA Compliance 772 1Pharmaceutical Manufacturing Quality 3A Optimizing Your Internal Process for FDA Compliance 772 2Rain Man mice provide model for autism 771 1Rain Man mice provide model for autism 771 2
...(BUSINESS WIRE)--Jun 25, 2007 - Gilead,Sciences, I...a,Phase III clinical trial evaluating the company,...soproxil fumarate or tenofovir,DF) 300 mg as a pot...V) infection, met its primary efficacy endpoint. T...mpany,s once-daily antiviral,drug Hepsera(R) (adef...
...icates 20-50% Improvement in Post-Preservation,Fun...r Cancer,Therapy, BOTHELL, Wash., June 25, 2007 /P... leading developer and marketer of proprietary,hyp...ts for cells,tissues, and organs, today presented...mily of cryopreservation media at the annual,meeti...
Other Medicine Technology:Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 2BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 3BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 4